As clinical trials grow increasingly complex, sponsors are turning to specialist CROs with the expertise to transform data into regulatory-grade evidence. In this article for The Medicine Maker, Stephen Corson, Associate Director of Statistics & Technical Solutions at Phastar, discusses how the CRO model is evolving, from transactional service delivery to strategic partnership, helping sponsors accelerate development timelines, enhance data quality, and navigate growing trial complexity with confidence.
”Sponsors need a CRO that has deep therapeutic expertise and regulatory knowledge, and that can accelerate drug development timelines without compromising on data quality or integrity. In many cases, sponsors are looking for specialists. Almost 8 in 10 pharma and biotech companies feel a ‘one-stop shop’ CRO model is no longer cost effective, with biotech companies, in particular, feeling that big CROs are failing to deliver.”